ID30064A - Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion - Google Patents

Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Info

Publication number
ID30064A
ID30064A IDW00200101331A ID20011331A ID30064A ID 30064 A ID30064 A ID 30064A ID W00200101331 A IDW00200101331 A ID W00200101331A ID 20011331 A ID20011331 A ID 20011331A ID 30064 A ID30064 A ID 30064A
Authority
ID
Indonesia
Prior art keywords
crystal
methyl
tiazolidinedion
fluorobenzil
oksi
Prior art date
Application number
IDW00200101331A
Other languages
English (en)
Indonesian (id)
Inventor
Takayuki Oe
Hiroaki Ueno
Akira Maruyama
Katsuhiko Masuda
Original Assignee
Mitsibishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsibishi Chemical Corp filed Critical Mitsibishi Chemical Corp
Publication of ID30064A publication Critical patent/ID30064A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cosmetics (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IDW00200101331A 1998-11-20 1999-11-19 Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion ID30064A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20

Publications (1)

Publication Number Publication Date
ID30064A true ID30064A (id) 2001-11-01

Family

ID=18233859

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101331A ID30064A (id) 1998-11-20 1999-11-19 Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Country Status (23)

Country Link
US (3) US6541493B1 (tr)
EP (1) EP1131310B1 (tr)
JP (1) JP3784001B2 (tr)
KR (1) KR100652326B1 (tr)
CN (1) CN1326449A (tr)
AT (1) ATE315552T1 (tr)
AU (1) AU1185100A (tr)
BR (1) BR9916795A (tr)
CA (1) CA2351727C (tr)
CZ (1) CZ20011763A3 (tr)
DE (1) DE69929476T2 (tr)
ES (1) ES2257104T3 (tr)
HU (1) HUP0104139A3 (tr)
ID (1) ID30064A (tr)
IL (1) IL143177A0 (tr)
NO (1) NO20012444L (tr)
NZ (1) NZ512429A (tr)
PL (1) PL348502A1 (tr)
PT (1) PT1131310E (tr)
TR (4) TR200202110T2 (tr)
TW (2) TWI250156B (tr)
WO (1) WO2000031055A1 (tr)
ZA (1) ZA200104081B (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9916795A (pt) * 1998-11-20 2002-04-09 Mitsubishi Chem Corp Cristais de 5-{{6-( 2-fluorobenzil) oxi-2- naftil} metil} -2,4- tiazolidinodiona
AU1776701A (en) * 1999-11-19 2001-05-30 Ortho-Mcneil Pharmaceutical, Inc. Solid state forms of 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4- thiazolidinedione
CN100577175C (zh) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
CA2712574C (en) 2008-02-04 2014-01-07 Pfizer Limited Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
BR9916795A (pt) * 1998-11-20 2002-04-09 Mitsubishi Chem Corp Cristais de 5-{{6-( 2-fluorobenzil) oxi-2- naftil} metil} -2,4- tiazolidinodiona

Also Published As

Publication number Publication date
DE69929476D1 (de) 2006-04-06
ATE315552T1 (de) 2006-02-15
TWI250156B (en) 2006-03-01
TR200202110T2 (tr) 2002-10-21
TR200202103T2 (tr) 2002-11-21
NZ512429A (en) 2003-11-28
TW200613291A (en) 2006-05-01
HUP0104139A3 (en) 2003-12-29
NO20012444D0 (no) 2001-05-18
PL348502A1 (en) 2002-05-20
IL143177A0 (en) 2002-04-21
TWI272944B (en) 2007-02-11
KR20010101033A (ko) 2001-11-14
CA2351727C (en) 2008-09-23
JP3784001B2 (ja) 2006-06-07
ES2257104T3 (es) 2006-07-16
PT1131310E (pt) 2006-05-31
EP1131310B1 (en) 2006-01-11
NO20012444L (no) 2001-07-18
TR200101901T2 (tr) 2002-04-22
BR9916795A (pt) 2002-04-09
WO2000031055A1 (en) 2000-06-02
US20030158241A1 (en) 2003-08-21
EP1131310A1 (en) 2001-09-12
KR100652326B1 (ko) 2006-11-29
AU1185100A (en) 2000-06-13
CN1326449A (zh) 2001-12-12
US6541493B1 (en) 2003-04-01
DE69929476T2 (de) 2006-09-14
ZA200104081B (en) 2002-05-20
US20060149075A1 (en) 2006-07-06
TR200202109T2 (tr) 2002-11-21
HUP0104139A2 (hu) 2002-03-28
CA2351727A1 (en) 2000-06-02
JP2002530392A (ja) 2002-09-17
CZ20011763A3 (cs) 2001-10-17

Similar Documents

Publication Publication Date Title
FI970825A7 (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyö tyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
HUP0203431A3 (en) Novel heterocyclic compounds and salts thereof and pharmaceutical compositions containing and use of the same
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
IE831085L (en) Terahydroquinoline derivatives and their 'o' and 's'¹analogues
FI911646A7 (fi) DTPA-monoamideja, näitä yhdisteitä sisältäviä farmaseuttisia aineita, niiden käyttö ja menetelmä niiden valmistamiseksi
NZ240378A (en) Substituted thiazolidinedione derivatives; pharmaceutical compositions,
EA200000656A1 (ru) Замещенное производное тиазолидиндиона, способ его получения и его фармацевтическое применение
CA2130174A1 (en) 4-oxo-2 thioxoimidazolidine derivatives as inhibitors of blood platelet aggregation
IL99393A0 (en) Thiazolidine derivatives,methods for the preparation thereof and pharmaceutical composition containing the same
EA200000654A1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси]бензил]-тиазолидин-2,4-диона в качестве фармацевтического препарата
BR9813604A (pt) Hidrato de sal de ácido maleico 5-[4-[2- (n-metil-n-(2-piridil) amino) etóxi]benzil]tiazolidina-2,4-diona
ID30064A (id) Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion
EA200101101A1 (ru) Новый фармацевтический препарат
ZA845723B (en) Compounds for lowering lipid levels
IT1303793B1 (it) "composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico (no)"
IL77051A (en) Crystalline form of the monoethanolamine salt of n-(2-pyridyl)-2-methyl-4-hydroxy-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide and pharmaceutical compositions containing it
EE03090B1 (et) Kinoliin-3-karboksamiidühendite kasutamine kompositsiooni valmistamiseks I tüüpi suhkurtõve raviks
EP0256507A3 (en) 3-(1h-tetrazol-5-yl)oxanilic acid and salts thereof, method for preparing the same and pharmaceutical compositions containing the compound
GB9014532D0 (en) Thiazole compound,processes for the preparation thereof and pharmaceutical composition comprising the same
IL67564A0 (en) (1,2)-fused 1,4-benzodiazepine compounds,their preparation and pharmaceutical compositions containing them
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy
JPS57206683A (en) Pyrimidone salt, manufacture and medicinal composition containing same
NO970477D0 (no) Inhibisjon av leukotrien biosyntese med ureaderivater
JPS57140785A (en) Benzothiazine derivative, its preparation, and pharmaceutical composition containing the same
AU6740187A (en) Heterocyclic compounds, methods for the manufacture of the same and pharmaceutical compositions containing the same